Home / Candesartan / Canada
CA ATC C09CA06 · updated 2 Nov 2026
Candesartan shortage in Canada
Is there a Candesartan shortage in Canada?
Yes. As of 2 Nov 2026, 27 Candesartan products are reported short in Canada, the first since 15 Sep 2016. The company estimate for the return is 6 Nov 2026. Main reason: manufacturing problem.
Also short in Germany, Italy, Spain, Austria, Czechia, Sweden, Japan, New Zealand, Australia. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | JAMP-CANDESARTAN (30) | JAMP PHARMA CORPORATION | 15 Sep 2016 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACH-CANDESARTAN (100) | ACCORD HEALTHCARE INC | 25 Apr 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACCEL-CANDESARTAN (100 tablets) | ACCEL PHARMA INC | 6 Jun 2019 | not given | Other Other (Please describe in comments) |
| CA | ACCEL-CANDESARTAN (100 tablets) | ACCEL PHARMA INC | 6 Jun 2019 | not given | Other Other (Please describe in comments) |
| CA | ACCEL-CANDESARTAN (100 tablets) | ACCEL PHARMA INC | 6 Jun 2019 | not given | Other Other (Please describe in comments) |
| CA | APO-CANDESARTAN (100 BTL) | APOTEX INC | 18 Oct 2021 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN (30 BLS) | APOTEX INC | 8 Mar 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN (100 BTL and 30 BLS) | APOTEX INC | 9 Aug 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN (100 BTL and 30 BLS) | APOTEX INC | 9 Aug 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN (100 BTL and 30 BLS) | APOTEX INC | 9 Aug 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACH-CANDESARTAN (100) | ACCORD HEALTHCARE INC | 26 Jan 2024 | not given | Increased demand Demand increase for the drug |
| CA | ACH-CANDESARTAN (100) | ACCORD HEALTHCARE INC | 22 Mar 2024 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | CANDESARTAN (100) | SANIS HEALTH INC | 9 Apr 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | CANDESARTAN (100) | SANIS HEALTH INC | 11 May 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | CANDESARTAN (100) | SANIS HEALTH INC | 3 Jul 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | CANDESARTAN (500) | SANIS HEALTH INC | 23 Aug 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | CANDESARTAN (100) | SANIS HEALTH INC | 30 Aug 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | CANDESARTAN (500) | SANIS HEALTH INC | 9 Sep 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACH-CANDESARTAN (100) | ACCORD HEALTHCARE INC | 6 Dec 2024 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | APO-CANDESARTAN TABLETS (100 BTL) | APOTEX INC | 19 Aug 2025 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (30 BLS) | APOTEX INC | 14 Oct 2025 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (100 BTL) | APOTEX INC | 3 Feb 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (30 BLS) | APOTEX INC | 3 Feb 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (30 BLS) | APOTEX INC | 24 Mar 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (30 BLS) | APOTEX INC | 21 Apr 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-CANDESARTAN TABLETS (100 BTL) | APOTEX INC | 28 Apr 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | TARO-CANDESARTAN (100's bottle) | SUN PHARMA CANADA INC | 1 Sep 2026 | 6 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.